Genetics for performance
@iamsajeev urged creators to explore genetic testing for peak performance, flagging GSTM1 for detox, Akkermansia for gut‑brain health, and zinc metabolism for diabetes and cognitive decline prevention (x.com). Those specifics are great hooks for evidence‑backed creator content — think testing protocols, expert interviews, and sponsored lab partnerships (x.com).
Specialized labs now sell targeted GSTM1 genotyping as a standalone or panel add‑on — Stride lists a dedicated GSTM1 gene test for detoxification context. (getstride.com) Published population studies show the GSTM1 “null” deletion occurs in roughly 42–57% of Asians and Caucasians and about 16–36% of people of African ancestry, highlighting large ethnic variation in who would test positive for deletion. (link.springer.com) Clinical research has used GSTM1/GSTT1 genotyping to stratify chemotherapy risk, including reports that GSTM1 and GSTT1 deficiencies worsen cisplatin‑induced nephrotoxicity in preclinical and translational studies. (frontiersin.org) Multiple consumer microbiome services now report Akkermansia abundance from stool sequencing and offer interpretive reports and follow‑up consultations, including GDX’s Akkermansia assessment and Viome’s at‑home microbiome test. (connect.gdx.net) (viome.com) Genetic work on zinc transport implicates SLC30A8 variants in type 2 diabetes risk and therapeutic biology, with loss‑of‑function SLC30A8 alleles shown in large sequencing studies to reduce diabetes risk and the common rs13266634 SNP repeatedly associated with glycemic traits. (nature.com) (bots.snpedia.com) Major direct‑to‑consumer genetics providers and test vendors already engage creators and influencer channels for marketing and education, and industry playbooks and platform reports list structured sponsored partnership models that creators can use to monetize testing content. (23andme.com) (upfluence.com)
